These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 2329563

  • 21. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
    Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL.
    J Med Chem; 1994 Nov 11; 37(23):3977-85. PubMed ID: 7966158
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and antidiabetic activity of novel 2,4-thiazolidinedione derivatives containing a thiazole ring.
    Bozdağ-Dündar O, Ceylan-Unlüsoy M, Verspohl EJ, Ertan R.
    Arzneimittelforschung; 2006 Nov 11; 56(9):621-5. PubMed ID: 17063636
    [Abstract] [Full Text] [Related]

  • 23. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ, Lefèbvre PJ.
    Diabetes Care; 1999 Sep 11; 22(9):1568-77. PubMed ID: 10480527
    [Abstract] [Full Text] [Related]

  • 24. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds.
    Momose Y, Meguro K, Ikeda H, Hatanaka C, Oi S, Sohda T.
    Chem Pharm Bull (Tokyo); 1991 Jun 11; 39(6):1440-5. PubMed ID: 1934164
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K.
    Eur J Pharmacol; 1999 Jan 08; 364(2-3):211-9. PubMed ID: 9932726
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives--fifth communication: flavonyl benzyl substituted 2,4-thiazolidinediones.
    Tunçbilek M, Bozdağ-Dündar O, Ayhan-Kilcigil G, Ceylan M, Waheed A, Verspohl EJ, Ertan R.
    Farmaco; 2003 Jan 08; 58(1):79-83. PubMed ID: 12595040
    [Abstract] [Full Text] [Related]

  • 30. Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship.
    Yanagisawa H, Takamura M, Yamada E, Fujita S, Fujiwara T, Yachi M, Isobe A, Hagisawa Y.
    Bioorg Med Chem Lett; 2000 Feb 21; 10(4):373-5. PubMed ID: 10714503
    [Abstract] [Full Text] [Related]

  • 31. Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones.
    Oguchi M, Wada K, Honma H, Tanaka A, Kaneko T, Sakakibara S, Ohsumi J, Serizawa N, Fujiwara T, Horikoshi H, Fujita T.
    J Med Chem; 2000 Aug 10; 43(16):3052-66. PubMed ID: 10956213
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Synthesis and hypoglycemic activity of some new flavone derivatives. 2nd communication: 4'-flavonyl-2,4-thiazolidinediones.
    Bozdağ O, Verspohl EJ, Ertan R.
    Arzneimittelforschung; 2000 Jun 10; 50(6):539-43. PubMed ID: 10918947
    [Abstract] [Full Text] [Related]

  • 34. Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone.
    Hulin B, Newton LS, Lewis DM, Genereux PE, Gibbs EM, Clark DA.
    J Med Chem; 1996 Sep 27; 39(20):3897-907. PubMed ID: 8831756
    [Abstract] [Full Text] [Related]

  • 35. Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif.
    Reddy KA, Lohray BB, Bhushan V, Reddy AS, Kishore PH, Rao VV, Saibaba V, Bajji AC, Rajesh BM, Reddy KV, Chakrabarti R, Rajagopalan R.
    Bioorg Med Chem Lett; 1998 May 05; 8(9):999-1002. PubMed ID: 9871696
    [Abstract] [Full Text] [Related]

  • 36. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
    Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR, Ogilvie KM, Liu S, Kauffman RF.
    Diabetes; 2002 Apr 05; 51(4):1083-7. PubMed ID: 11916929
    [Abstract] [Full Text] [Related]

  • 37. Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties.
    Jawale DV, Pratap UR, Rahuja N, Srivastava AK, Mane RA.
    Bioorg Med Chem Lett; 2012 Jan 01; 22(1):436-9. PubMed ID: 22123321
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.